BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 20095945)

  • 1. What should be considered on design of a colon-specific prodrug?
    Jung Y; Kim YM
    Expert Opin Drug Deliv; 2010 Feb; 7(2):245-58. PubMed ID: 20095945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical approaches to colon targeted drug delivery systems.
    Chourasia MK; Jain SK
    J Pharm Pharm Sci; 2003; 6(1):33-66. PubMed ID: 12753729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Research of oral prodrugs: opportunities and challenges].
    Cao F; Ping QN; Chen J
    Yao Xue Xue Bao; 2008 Apr; 43(4):343-9. PubMed ID: 18664193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiparticulate formulation approach to colon specific drug delivery: current perspectives.
    Asghar LF; Chandran S
    J Pharm Pharm Sci; 2006; 9(3):327-38. PubMed ID: 17207416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis.
    Lee Y; Kim H; Kim W; Yoon JH; Jeong SH; Jung Y
    J Drug Target; 2012 Jul; 20(6):524-34. PubMed ID: 22632102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis.
    Jung Y; Kim HH; Kim H; Kong H; Choi B; Yang Y; Kim Y
    Eur J Pharm Sci; 2006 May; 28(1-2):26-33. PubMed ID: 16455235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prodrug strategies in anticancer chemotherapy.
    Kratz F; Müller IA; Ryppa C; Warnecke A
    ChemMedChem; 2008 Jan; 3(1):20-53. PubMed ID: 17963208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do prodrugs deliver?
    Smith DA
    Curr Opin Drug Discov Devel; 2007 Sep; 10(5):550-9. PubMed ID: 17786853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel prospective in colon specific drug delivery system.
    Bansal V; Malviya R; Malaviya T; Sharma PK
    Polim Med; 2014; 44(2):109-18. PubMed ID: 24967782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and properties of polysaccharide prodrugs of 5-aminosalicylic acid as potential colon-specific delivery systems.
    Zou M; Okamoto H; Cheng G; Hao X; Sun J; Cui F; Danjo K
    Eur J Pharm Biopharm; 2005 Jan; 59(1):155-60. PubMed ID: 15567313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies to improve oral drug bioavailability.
    Gomez-Orellana I
    Expert Opin Drug Deliv; 2005 May; 2(3):419-33. PubMed ID: 16296764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing delivery of flurbiprofen to the colon using a targeted prodrug approach.
    Philip AK; Dubey RK; Pathak K
    J Pharm Pharmacol; 2008 May; 60(5):607-13. PubMed ID: 18416937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prodrug strategies to overcome poor water solubility.
    Stella VJ; Nti-Addae KW
    Adv Drug Deliv Rev; 2007 Jul; 59(7):677-94. PubMed ID: 17628203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colonic drug delivery: an updated review.
    Shareef MA; Khar RK; Ahuja A; Ahmad FJ; Raghava S
    AAPS PharmSci; 2003; 5(2):E17. PubMed ID: 12866944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral colon targeted delivery systems for treatment of inflammatory bowel diseases: synthesis, in vitro and in vivo assessment.
    El-Kamel AH; Abdel-Aziz AA; Fatani AJ; El-Subbagh HI
    Int J Pharm; 2008 Jun; 358(1-2):248-55. PubMed ID: 18502065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prodrugs: design and clinical applications.
    Rautio J; Kumpulainen H; Heimbach T; Oliyai R; Oh D; Järvinen T; Savolainen J
    Nat Rev Drug Discov; 2008 Mar; 7(3):255-70. PubMed ID: 18219308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orally active factor Xa inhibitors: investigation of a novel series of 3-amidinophenylsulfonamide derivatives using an amidoxime prodrug strategy.
    Uchida M; Okazaki K; Mukaiyama H; Isawa H; Kobayashi H; Shiohara H; Muranaka H; Kai Y; Kikuchi N; Takeuchi H; Yokoyama K; Tsuji E; Ozawa T; Hoyano Y; Koizumi T; Misawa K; Hara K; Nakano S; Murakami Y; Okuno H
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4682-7. PubMed ID: 18667303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
    Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
    J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting drugs to the colon: delivery systems for oral administration.
    Ashford M; Fell JT
    J Drug Target; 1994; 2(3):241-57. PubMed ID: 7812693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colonic drug targeting.
    Kinget R; Kalala W; Vervoort L; van den Mooter G
    J Drug Target; 1998; 6(2):129-49. PubMed ID: 9886237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.